Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
Key takeaways
- Jim Cramer on Regeneron: “There Could Be Some More Downgrades” Syeda Seirut Javed Thu, May 21, 2026 at 8:12 PM GMT+7 1 min read REGN Regeneron Pharmaceuticals, Inc.
- Finally, there’s Regeneron, which got blasted by a poor result on a metastatic melanoma cancer trial.
- Photo by Arturo A on Pexels Regeneron Pharmaceuticals, Inc.
Jim Cramer on Regeneron: “There Could Be Some More Downgrades” Syeda Seirut Javed Thu, May 21, 2026 at 8:12 PM GMT+7 1 min read REGN Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was among the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation. Cramer highlighted the company’s unsuccessful trial, as he remarked:
Finally, there’s Regeneron, which got blasted by a poor result on a metastatic melanoma cancer trial. I, along with many others, thought that this trial would succeed. You can’t buy a drug stock that falls that much on the first day of the decline. Most analysts seem to have keyed on this drug to recommend the stock. It’s damaged. There could be some more downgrades.
A stock market chart. Photo by Arturo A on Pexels Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. A caller asked for Cramer’s thoughts on the company during the April 9 episode. The Mad Money host responded: